Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 2481 to 2490 of 2610 total matches.
Echinacea for Prevention and Treatment of Upper Respiratory Infections
The Medical Letter on Drugs and Therapeutics • Apr 01, 2002 (Issue 1127)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Echinacea, a plant also called purple coneflower, is widely used as a dietary supplement for prevention and treatment of colds.
Pediarix - a Combined Vaccine for Infants
The Medical Letter on Drugs and Therapeutics • May 12, 2003 (Issue 1156)
The Medical Letter
On Drugs and Therapeutics
www.medicalletter.org
Published by The Medical ...
A new pentavalent vaccine (Pediarix - GlaxoSmithKline), licensed by the FDA for children 6 weeks to 7 years old, includes the antigens from vaccines already marketed against diphtheria, tetanus and pertussis (Infanrix) and hepatitis B (Engerix-B), and a new inactivated polio component.
Copyright Violations
The Medical Letter on Drugs and Therapeutics • Apr 29, 2002 (Issue 1129)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
The Medical Letter is a nonprofit organization supported entirely by subscription fees and sales of books, software and individual issues. We do not accept advertisements, grants, donations or gifts. We do not sell large numbers of reprints to pharmaceutical manufacturers.
We ask our readers to respect our copyright. We offer electronic access to our issues to individual subscribers and, for a reasonable fee, site licenses for electronic access to organizations like pharmaceutical companies and universities.
In Brief: Delayed-Release Risedronate (Atelvia)
The Medical Letter on Drugs and Therapeutics • Mar 21, 2011 (Issue 1360)
The Medical Letter®
On Drugs and Therapeutics
Volume 53 (Issue 1360)
March 21, 2011 ...
A new enteric-coated delayed-release formulation of risedronate (Atelvia – Warner Chilcott) has been approved by the FDA for treatment of postmenopausal osteoporosis. Unlike immediate-release risedronate (Actonel) and all other oral bisphosphonates, which must be taken after an overnight fast and at least 30 minutes before eating breakfast, the new formulation is taken immediately after breakfast with at least 4 ounces of water. Then the patient must remain upright for at least 30 minutes.CLINICAL TRIAL — Approval of Atelvia was based on a 52-week non-inferiority study in more than 900...
In Brief: Duopa - A Carbidopa/Levodopa Enteral Suspension for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Aug 03, 2015 (Issue 1474)
, Inc. All
rights reserved. ©2015. www.fdbhealth.com/policies/drug-pricing-policy.
3. F Valldeoriola ...
The FDA has approved Duopa (Abbvie), a carbidopa/levodopa enteral suspension, for treatment of motor fluctuations in patients with advanced Parkinson's disease (PD). It has been available in Europe since 2001.In patients with advanced PD, emptying of the stomach may be delayed and unpredictable, which can affect the rate and amount of absorption of carbidopa/levodopa and its efficacy. To bypass the stomach, the new formulation is delivered through a nasojejunal (NJ) tube or percutaneous endoscopic gastrostomy with jejunal (PEG-J) tube.A randomized, double-blind, active-controlled, 12-week...
Ruxolitinib (Opzelura) for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
old whose disease has not been
adequately controlled with other topical prescription
drugs ...
The FDA has approved a 1.5% topical cream
formulation of the Janus kinase (JAK) inhibitor
ruxolitinib (Opzelura – Incyte) for short-term, non-continuous
chronic treatment of mild to moderate
atopic dermatitis (AD) in non-immunocompromised
patients ≥12 years old whose disease has not been
adequately controlled with other topical prescription
drugs. Ruxolitinib is the first JAK inhibitor to be
approved for topical use and the first to be approved
in the US for treatment of AD. An oral formulation
of ruxolitinib (Jakafi) is approved for treatment of
myelofibrosis, polycythemia...
Ibritumomab Tiuxetan (Zevalin) for Non-Hodgkin's Lymphoma
The Medical Letter on Drugs and Therapeutics • Nov 25, 2002 (Issue 1144)
The Medical Letter
On Drugs and Therapeutics
www.medicalletter.org
Published by The Medical ...
Yttrium-90 ibritumomab tiuxetan (Zevalin -IDEC) was approved by the FDA for treatment of patients with relapsed or refractory low-grade follicular or transformed B-cell non-Hodgkin's lymphoma (NHL), including patients with follicular lymphoma refractory to rituximab (Rituxan -Medical Letter 1998; 40:65). Zevalin is the first radioimmunoconjugate to be approved for treatment of cancer.
Lowering Plasma Homocysteine
The Medical Letter on Drugs and Therapeutics • Oct 27, 2003 (Issue 1168)
of folate (1 mg), vitamin B
6
(10
85
The Medical Letter
®
On Drugs and Therapeutics ...
High plasma homocysteine concentrations, like high cholesterol, have been associated with an increased risk of cardiovascular disease and death (O Nygσrd et al, N Engl J Med 1997; 337:230; RS Vasan et al, JAMA 2003; 289:1251). In one meta-analysis, 25% lower plasma homocysteine concentrations were associated with 11% less coronary heart disease and 19% less stroke (Homocysteine Studies Collaboration, JAMA 2002; 288:2015). Should we be trying to lower serum homocysteine concentrations in our patients?
PSA Reconsidered
The Medical Letter on Drugs and Therapeutics • Aug 06, 2012 (Issue 1396)
The Medical Letter®
On Drugs and Therapeutics
Volume 54 (Issue 1396)
August 6, 2012 ...
Three recent publications have focused attention once
more on the contentious question of whether men
should be screened for prostate cancer by measuring
serum concentrations of prostate specific antigen (PSA).
In Brief: Johnson & Johnson COVID-19 Vaccine Suspended (online only)
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
vaccination. N Engl J Med 2021 April 9 (epub). vaccines drug safety COVID-19 ...
On April 13, 2021, the FDA and CDC advised suspending
use of the Johnson & Johnson adenovirus-based
COVID-19 vaccine while the agencies investigate 6
cases of cerebral venous sinus thrombosis (CVST) and
thrombocytopenia that occurred following administration
of the vaccine. In an April 14 emergency meeting,
the Advisory Committee on Immunization Practices
(ACIP) recommended continuing the suspension until
more data become available. About 7 million people in
the US have received the Johnson & Johnson vaccine.